TSE:HLS HLS Therapeutics (HLS) Stock Price, News & Analysis C$3.20 -0.01 (-0.31%) (As of 09/6/2024 ET) Add Compare Share Share Today's RangeC$3.06▼C$3.2150-Day RangeC$3.01▼C$3.6552-Week RangeC$3.00▼C$5.52Volume4,851 shsAverage Volume25,849 shsMarket CapitalizationC$101.73 millionP/E RatioN/ADividend Yield6.25%Price TargetC$3.63 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider Trades Get HLS Therapeutics alerts: Email Address HLS Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside13.3% UpsideC$3.63 Price TargetShort InterestN/ADividend StrengthWeakBased on Four FactorsSustainabilityN/ANews SentimentN/AInsider TradingAcquiring SharesC$3,828 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.70 out of 5 stars 2.2 Analyst's Opinion Consensus RatingHLS Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageHLS Therapeutics has received no research coverage in the past 90 days.Read more about HLS Therapeutics' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for HLS. Previous Next 1.7 Dividend Strength Dividend LeadershipHLS Therapeutics is a leading dividend payer. It pays a dividend yield of 4.30%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthHLS Therapeutics does not have a long track record of dividend growth.Read more about HLS Therapeutics' dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HLS. Previous Next 0.8 News and Social Media Coverage News SentimentHLS Therapeutics has a news sentiment score of -0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, HLS Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought C$3,828.00 in company stock and sold C$0.00 in company stock.Percentage Held by InsidersOnly 0.37% of the stock of HLS Therapeutics is held by insiders.Percentage Held by Institutions65.25% of the stock of HLS Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about HLS Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of HLS Therapeutics is -3.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of HLS Therapeutics is -3.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHLS Therapeutics has a P/B Ratio of 1.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about HLS Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.>> Get Your FREE Wealth Protection Guide << About HLS Therapeutics Stock (TSE:HLS)HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.Read More HLS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HLS Stock News HeadlinesAugust 28, 2024 | finance.yahoo.comHLS Therapeutics to Present at H.C. Wainwright's 26th Annual Global Investment ConferenceAugust 23, 2024 | finance.yahoo.comHLS Therapeutics Inc. (74D.F)September 7, 2024 | Weiss Ratings (Ad)“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.August 13, 2024 | msn.comFDA gives thumbs down to MDMA for now, demanding further researchAugust 8, 2024 | finance.yahoo.comHLS Therapeutics Announces Q2 2024 Financial ResultsAugust 1, 2024 | msn.comAmarin Corporation plc (NASDAQ:AMRN) Q2 2024 Earnings Call TranscriptJuly 31, 2024 | msn.comAmarin Plc (AMRN) Q2 2024 Earnings Call TranscriptJuly 29, 2024 | finance.yahoo.comHLS Announces Reimbursement for Vascepa® under Alberta's Provincial Drug PlanSeptember 7, 2024 | Weiss Ratings (Ad)“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.July 25, 2024 | sg.finance.yahoo.comFTSE 100 LIVE: European stocks slump after Wall Street suffers worst sell-off in over a yearJuly 25, 2024 | ca.finance.yahoo.comHLS Therapeutics to Host Q2 Fiscal 2024 Financial Results Conference CallJuly 19, 2024 | theglobeandmail.comClosing Bell: Hls Therapeutics Inc flat on Wednesday (HLS)May 28, 2024 | finance.yahoo.comNew Study Published on the Impact of Pharmaceutical Support Programs on Persistence with Clozapine TreatmentMay 9, 2024 | morningstar.comHLS Therapeutics Inc HLSMay 9, 2024 | finance.yahoo.comHLS Therapeutics Announces Q1 2024 Financial ResultsApril 9, 2024 | finance.yahoo.comHLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceApril 8, 2024 | finance.yahoo.comNew REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient SubgroupsMarch 17, 2024 | finance.yahoo.comEarnings Release: Here's Why Analysts Cut Their HLS Therapeutics Inc. (TSE:HLS) Price Target To CA$6.57See More Headlines Receive HLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HLS Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:HLS CUSIPN/A CIKN/A Webwww.hlstherapeutics.com Phone647-495-9000FaxN/AEmployees91Year FoundedN/APrice Target and Rating Average Stock Price TargetC$3.63 High Stock Price TargetC$4.00 Low Stock Price TargetC$3.25 Potential Upside/Downside+13.3%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)C($1.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-24,090,000.00 Net Margins-40.90% Pretax MarginN/A Return on Equity-24.82% Return on Assets-2.89% Debt Debt-to-Equity Ratio100.44 Current Ratio2.02 Quick Ratio1.01 Sales & Book Value Annual SalesC$58.89 million Price / Sales1.73 Cash FlowC$0.21 per share Price / Cash Flow15.22 Book ValueC$2.60 per share Price / Book1.23Miscellaneous Outstanding Shares31,790,000Free FloatN/AMarket CapC$101.73 million OptionableNot Optionable Beta1.05 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Jason A. Gross Pharm.D. (Age 59)Vice President of Scientific Affairs Comp: $357.86kMr. Ryan C. Lennox B.A. (Age 43)J.D., Senior VP of Legal, HR & Compliance and Corporate Secretary Comp: $393.31kMr. Craig Stuart Millian M.B.A. (Age 56)CEO & Director Mr. John Hanna CPACGA, M.B.A., Interim CFO & Non-Independent DirectorBrian T. WalshSenior Vice President of CommercialMr. David Spence (Age 56)VP & Corporate Controller More ExecutivesKey CompetitorsSupreme CannabisTSE:FIREOrganigramTSE:OGIESSA PharmaCVE:EPIICC LabsCVE:ICCRIV CapitalTSE:RIVView All CompetitorsInsidersJohn Gordon HannaBought 1,200 shares on 8/14/2024Total: C$3,828.00 ($3.19/share)Craig MillianBought 2,500 shares on 5/15/2024Total: C$7,250.00 ($2.90/share)Craig MillianBought 5,000 shares on 11/16/2023Total: C$13,000.00 ($2.60/share)Brian Thomas WalshBought 1,000 shares on 11/15/2023Total: C$2,910.00 ($2.91/share)Polar Asset Management Partners Inc.Bought 20,000 shares on 11/10/2023Total: C$86,000.00 ($4.30/share)View All Insider Transactions HLS Stock Analysis - Frequently Asked Questions How have HLS shares performed this year? HLS Therapeutics' stock was trading at C$3.95 on January 1st, 2024. Since then, HLS shares have decreased by 19.0% and is now trading at C$3.20. View the best growth stocks for 2024 here. How were HLS Therapeutics' earnings last quarter? HLS Therapeutics Inc. (TSE:HLS) posted its quarterly earnings results on Thursday, August, 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.25). The firm earned $19.87 million during the quarter, compared to analysts' expectations of $19.25 million. HLS Therapeutics had a negative trailing twelve-month return on equity of 24.82% and a negative net margin of 40.90%. How do I buy shares of HLS Therapeutics? Shares of HLS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What other stocks do shareholders of HLS Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that HLS Therapeutics investors own include Cargojet (CJT), Fairfax Financial (FFH), Fortis (FTS), Aurora Cannabis (ACB), Aphria (APHA), Alimentation Couche-Tard (ATD.B) and BlackBerry (BB). This page (TSE:HLS) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HLS Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share HLS Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
